Evidence map›Paper›PMID 30338039›Full record

ArticleOncotarget2018

Inhibitory effects of pentoxifylline on inflammation-related tumorigenesis in rat colon.

Yohei Shirakami, Takahiro Kochi, Masaya Kubota, Hiroyasu Sakai, Takashi Ibuka, Kazuto Yoshimi, Takashi Kuramoto, Takuji Tanaka, Masahito Shimizu, Mitsuru Seishima

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 12 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Yohei ShirakamiDepartment of Informative Clinical Medicine, Gifu University Graduate School of Medicine, Gifu 501-1194, Japan.
Takahiro KochiDepartment of Gastroenterology, Gifu University Graduate School of Medicine, Gifu 501-1194, Japan.
Masaya KubotaDepartment of Gastroenterology, Gifu University Graduate School of Medicine, Gifu 501-1194, Japan.
Hiroyasu SakaiDepartment of Gastroenterology, Gifu University Graduate School of Medicine, Gifu 501-1194, Japan.
Takashi IbukaDepartment of Gastroenterology, Gifu University Graduate School of Medicine, Gifu 501-1194, Japan.
Kazuto YoshimiGenome Editing Research and Development Center, Graduate School of Medicine, Osaka University, Osaka 565-0871, Japan.
Takashi KuramotoInstitute of Laboratory Animals, Graduate School of Medicine, Kyoto University, Kyoto 606-8501, Japan.
Takuji TanakaDepartment of Pathological Diagnosis, Gifu Municipal Hospital, Gifu 500-8513, Japan.
Masahito ShimizuDepartment of Gastroenterology, Gifu University Graduate School of Medicine, Gifu 501-1194, Japan.
Mitsuru SeishimaDepartment of Informative Clinical Medicine, Gifu University Graduate School of Medicine, Gifu 501-1194, Japan.
Gifu University · JPGifu Municipal Hospital · JPKyoto University · JPOsaka University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic inflammation in the colorectum increases the risk of colorectal cancer development. Pentoxifylline, a medicine used for improving the circulation, has been reported to inhibit TNF-α production and to ameliorate inflammatory bowel disease and non-alcoholic steatohepatitis. In this study, we investigated the effects of pentoxifylline on inflammation-related colon tumorigenesis in a rodent model using Kyoto APC delta rats, which have APC mutation and are susceptible to colon carcinogenesis. Male Kyoto APC delta rats were treated with azoxymethane and dextran sodium sulfate, and were subsequently administered water, with or without pentoxifylline. At the end of the experiment, the development of colorectal tumor was significantly inhibited in the pentoxifylline group. The pentoxifylline treatment also lowered the levels of oxidative stress markers and mRNAs of pro-inflammatory cytokines, including TNF-α and IL-6, in the colon mucosa. The PCNA labeling index and the inflammation score were also decreased in the colon of rats in the pentoxifylline -treated group. We also used an endoscopy to observe the tumor progression and inflammation in the colon of rats, revealing that inflammation grade was significantly lower in pentoxifylline-treated group at several points during the experiment. These findings suggest that pentoxifylline treatment might be useful for chemoprevention of inflammation-related colon cancer.

Indexed as

colorectal cancerinflammatory bowel disease (IBD)oxidative stresspentoxifylline

Identifiers

PMID30338039
PMCPMC6188053
OpenAlexW2890315792

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.